Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas

  1. Kazushi Inoue1,
  2. Frederique Zindy1,
  3. David H. Randle1,4,
  4. Jerold E. Rehg2, and
  5. Charles J. Sherr1,3,4,5
  1. Department of 1Tumor Cell Biology, 2Pathology, and 3Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA; 4Department of Molecular Sciences, University of Tennessee College of Medicine, Memphis, Tennessee 38163, USA

Abstract

Loss of Dmp1, an Arf transcriptional activator, leads to spontaneous tumorigenesis in mice, causing death from various forms of cancer by two years of age. Retention and expression of the wild-typeDmp1 allele in tumors arising in Dmp1 +/−mice demonstrate that Dmp1 can be haplo-insufficient for tumor suppression. The mean latency of Eμ-Myc-induced B-cell lymphomas is halved on a Dmp1 −/− orDmp1 +/− genetic background. Although p53mutations or Arf deletion normally occur in ∼50% of Eμ-Myc-induced lymphomas, Dmp1 loss obviates selection for such mutations, indicating that Dmp1 is a potent genetic modifier of the Arf–p53 pathway in vivo.

Keywords

Footnotes

  • 5 Corresponding author.

  • E-MAIL sherr{at}stjude.org; FAX (901) 495-2381.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.929901.

    • Received July 23, 2001.
    • Accepted September 6, 2001.
| Table of Contents

Life Science Alliance